HEALTH TECHNOLOGY

Northern Health and The Clinician Join Forces to Expand Their VVE Department

The Clinician | May 31, 2022

Northern Health

Digital health innovation platform, The Clinician, announced it is partnering with Northern Health, a prominent public healthcare provider. Northern Health is set to expand its Victorian Virtual Emergency Department (VVED). The organization has onboarded The Clinician as its technology partner to develop a new patient registration and intake portal as part of the expansion.

"Working with The Clinician has been absolutely fantastic. They have taken the time to understand the problem and have produced a bespoke product that has exceeded our expectations in both quality and timely delivery. Their team are extremely professional and have been very easy to work with. I look forward to potential future collaborations."

Loren Sher, Clinical Director of the Victorian Virtual Emergency Department

"Everyone can relate to the challenges of busy, in-person emergency departments, so our team is proud to be supporting Northern Health's VVED and enabling patients to access high quality care from home. We see this as a great example of how our platform can be flexibly configured to the unique digital health needs of hospitals and healthcare services and look forward to extending our digital transformation work with Northern Health into other exciting areas."

Tamaryn Hankinson, Chief Commercial Officer and Co-Founder of The Clinician

VVED’s expansion will cover the state of Victoria and follows the success of the program since it was launched in 2020. The results include

  • A wait time of 30 minutes on telehealth to be seen by a triage nurse
  • A discharge rate of 80% from the virtual ED followed by a 40% outright discharge and 40% directed to different services

Following the collaboration, PREM or a patient-reported experience measure was added along with integrations with existing information systems. Northern Health also aims to make the most of The Clinician’s platform to assist ambulatory professionals and other healthcare services in the hospital.
 

Spotlight

We embrace technology as the forefront of healthcare advancement. Our digital health solutions enable better outcomes through patient-centric care, optimize costs and improve experience for patients, and care staff.


Other News
DIGITAL HEALTHCARE, MEDICAL DEVICES

Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

Sharps Technology Inc | December 21, 2022

Sharps Technology, Inc. an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply. Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry. These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention. By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments. “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them." Robert Hayes, Sharps Technology CEO "We look forward to a bright future at Sharps Technology," concluded Mr. Hayes. "The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opportunity for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023." When healthcare providers use ultra-low waste syringes with multi-dose vials, it allows for the availability of up to 20% to 40% more medication for patients that need the treatment. This medication availability is created by using more efficient syringes designated as low-waste and ultra-low waste products, and not trapping medication within the syringe after the dose is given. The use of standard syringes that are not designated as low waste or ultra-low waste products typically creates a dead space area within the syringe where excess medication is trapped and cannot be used. This dead space then causes the healthcare provider to throw away the unused medication. The trapped medication in the dead space of a standard syringe can waste as much as 100 microliters of medication or more. The Pharmaceutical companies that fill their medication into vials understand this and must then overfill the vial with drug therapy to compensate for the problem. As the costs for medication and medical treatments rise, the discarded medication can cost the industry millions of dollars, or more, globally. The purchase of the European facility was finalized in the summer of 2022 and Sharps has invested in infrastructure and equipment upgrades to prepare the plant for a full manufacturing schedule. Syringe products produced by Sharps comply with all applicable FDA and ISO requirements and have been awarded the European Union’s CE Mark. The Sharps Hungary team, led by General Manager Filippo Filippi, brings together a dedicated and knowledgeable manufacturing force, with more than 20 years of experience in supplying the world with high quality, innovative syringe products. Prior to the GM position, Filippi’s career spanned years of building, managing, and supporting multiple manufacturing sites across Europe, Asia, and Africa. The Hungary plant is vertically integrated in that it has the capability to manufacture the syringe components by injection molding, assemble the devices on automated lines or by manual assembly if required, and to sterilize the products on-site through the Ethylene Oxide sterilization process. This last stage of the syringe manufacturing process is unique in the industry and gives Sharps an advantage in supporting shortened lead times as compared to the common need to utilize a third-party for sterilization. The plant has manufacturing capacity to supply more than 50 million units today and the facility could be expanded to produce 250 million units or more over the next couple of years. About Sharps Technology Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US..

Read More

FUTURE OF HEALTHCARE

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

Abbott | November 21, 2022

Abbott has been recognized by the Consumer Technology Association with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide. The CTA is the organization behind the Consumer Electronics Show the most influential technology event in the world. Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards, all within the Digital Health award category Aveir VR Leadless Pacemaker – The world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable. The system was developed by Abbott to treat patients with slow heart rhythms and eliminates wires used to deliver therapy in traditional pacemakers. Proclaim Plus SCS System – Abbott's latest advancement in neurostimulation therapy to treat chronic pain using low doses of targeted BurstDR™ stimulation that can be adjusted as a person's therapeutic needs evolve across up to six areas of the body, which is more pain sites in the body than ever before. Alinity m Monkeypox PCR test1 – A first of its kind, Abbott received FDA Emergency Use Authorization of its PCR test for detecting the monkeypox virus. The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products. The program recognizes the year's most innovative products in a multitude of consumer technology product categories and distinguishes the highest-rated in each. Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years. Other Abbott products previously honored with CES Innovation Awards include FreeStyle Libre 32, the world's smallest, thinnest3 and most accurate4 14-day glucose sensor and a CES 2022 Best of Innovation Award winner; BinaxNOW™5, the #1 COVID-19 self test in the U.S.; and the UltreonTM 1.0 intravascular imaging and coronary physiology software platform, which helps guide and optimize stenting decisions, combining optical coherence tomography with artificial intelligence. In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation. The FreeStyle Libre portfolio has transformed the lives of approximately 4.5 million people6 living with diabetes globally. About Abbott Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines.

Read More

FUTURE OF HEALTHCARE

Skylight Health Announces Series A Preferred Stock Cash Dividend

Skylight Health Group | December 14, 2022

Skylight Health Group Inc. a healthcare platform combining technology and analytics focused on transitioning patients into value based care to drive better health outcomes and experiences in the United States, announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares for the month of January 2023. The Series A Preferred Shares trade under the “SLHGP” stock ticker symbol. In accordance with the terms of the Series A Preferred Shares, the Series A dividend will be payable in cash in the amount of $0.1927 per share on January 20, 2023 to the shareholders of record of the Series A Preferred Stock as of the dividend record date of December 30, 2022. The Company also wishes to update details of the Company’s previously announced shares for debt on September 15 and 16, 2022. The Company will settle a total of $438,400 in debt by issuing an aggregate of 626,286 common shares to the creditors at a deemed price of $0.70 per common share, in satisfaction of the debt. About Skylight Health Group Skylight Health Group is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service model to value-based care (“VBC”) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on the volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimizing unnecessary health expenditures that are not proven to maintain the patient’s well-being. This places emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices.

Read More

DIGITAL HEALTHCARE, MEDICAL DEVICES

mPulse Expands Streaming Engagement Capabilities for Consumer-Focused Digital Health Content

mPulse Mobile, | December 16, 2022

mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, announced the launch of new content capabilities and streaming courses that address health literacy barriers in a consumer-friendly format. Several solution advances continue mPulse’s focus on integrating streaming content into digital health engagement strategies, creating an industry-leading combination of conversational AI that drives two-way SMS messaging campaigns and powerful health streaming content to engage, delight, and move consumers to adopt healthy behaviors. “Stories” Video Format mPulse launched the stories video format to deliver more impactful content experiences in consumer-focused outreach programs. The format adapts video “stories” commonly seen in social media platforms like TikTok and Instagram Reels to deliver captivating content on important healthcare topics. mPulse’s Health Activation Platform tailors the stories content to the individual to address important engagement challenges such as medication adherence, gaps in care, and health plan navigation. “These new video capabilities are proof that mPulse Mobile continues to pioneer category-defining member engagement technology. Our highly tailored, consumer focused content is a powerful tool that creates culturally sensitive digital experiences to address health disparities, encourage healthy behaviors, and drive member outcomes. The stories format allows us to be more impactful when consumers engage, and our initial results show they have a significant impact on program goals.” Bob Farrell, CEO of mPulse Mobile The format drives increased engagement and improved health outcomes among targeted populations. mPulse deployed the stories format in a diabetes eye-screening outreach program. The program included 200,000 Medicare Advantage members, with a subset of 100,000 members receiving the streaming content, delivered in a stories format. This cohort showed a 274% higher Call to Action completion rate than members who did not receive the stories-formatted content. Leveraging conversational outreach, consumers are prompted on the issues that might be preventing them from completing a given action. When they respond via text to identify a barrier, tailored streaming content is delivered instantly and in real-time via an embedded link to address the barrier. New Health Educational Courses mPulse has also launched new streaming health courses that address key health issues and improve health literacy in a consumer-friendly digital format. Produced with proven learning techniques and behavioral science, these courses allow healthcare organizations to extend the digital experience from initial outreach to deep, relationship-building experiences. “Our product strategy aims to offer the most effective technology at delivering health engagement, and core to mPulse’s value is meaningful digital content, which elevates engagement experiences to a new level,” said Sanjeev Sawai, Chief Product and Technology Officer at mPulse Mobile. “Members are in need of better educational content that they find engaging and worth their time. We use short, captivating content to get members' attention and motivate them to act in healthy ways - ways that help them build their health literacy, prevent diseases, manage conditions, and foster wellbeing. Our approach offers innovative frictionless ways to encourage members to engage deeply in their own health and healthcare.” About mPulse Mobile mPulse Mobile is reimagining health engagement to inspire healthier lives and deeper relationships between healthcare organizations and their consumers. A leading healthcare Conversational AI platform combines with award-winning health education for the streaming age to deliver tailored digital health engagement that nurtures, educates, and activates healthcare consumers. With more than a decade of experience, 150+ healthcare customers and 1 billion conversations annually, mPulse Mobile has the data, the expertise, and the solutions to drive healthy behavior change.

Read More

Spotlight

We embrace technology as the forefront of healthcare advancement. Our digital health solutions enable better outcomes through patient-centric care, optimize costs and improve experience for patients, and care staff.

Resources